Published in final edited form as:

Biochem Pharmacol. 2010 August 1; 80(3): 362–369. doi:10.1016/j.bcp.2010.04.015.

Altered Phospholipid Transfer Protein Gene Expression and Serum Lipid Profile by Topotecan

Rudel A. Saunders^{a,b}, Kazuyuki Fujii^{a,c}, Leah Alabanza^{a,d}, Roald Ravatn^a, Tsunekazu Kita^e, Kazuya Kudoh^c, Masahiro Oka^f, and Khew-Voon Chin^{a,b,*}

^a Department of Medicine, The University of Toledo, College of Medicine, Toledo, OH, United States

^b Center for Diabetes and Endocrine Research, The University of Toledo, College of Medicine, Toledo, OH United States

^c Department of Obstetrics and Gynecology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, Japan

^d Baker Institute for Animal Health, Cornell Veterinary College, Ithaca, NY, United States

^e Department of Gynecology, Saitama Cancer Center, Adachi-Gun, Japan

^f Division of Dermatology, Department of Clinical Molecular Medicine, Kobe University, Graduate School of Medicine, Kobe, Japan

Abstract

Camptothecin (CPT) and its structural analogues including topotecan and irinotecan, are inhibitors of topoisomerase I. These drugs are clinically active against a broad spectrum of cancers. To understand the genesis of chemotherapeutic resistance to the CPT family of anticancer drugs, we examined by gene expression profiling the pharmacological response to topotecan in the human hepatoma HepG2 cells and found a striking induction of the phospholipid transfer protein (PLTP) gene expression by topotecan. We showed that activation of PLTP gene expression is specific to CPT and its analogues including specific enantiomers that inhibit topoisomerase I. PLTP-mediated lipid transfer to high-density lipoprotein (HDL) is thought to be important for shuttling and redistribution of lipids between lipoproteins, which are normally returned to the liver for metabolism via the reverse cholesterol transport pathway. Hence, we asked whether elevated PLTP levels might increase the transfer of drugs into HDL. We observed that CPT was not accumulated in HDL and other lipoproteins. In addition, topotecan treatment in mice caused a marked reduction in serum HDL that was accompanied by an increase in triglyceride and cholesterol levels. These results showed that PLTP does not mediate the transfer of topoisomerase I inhibitors to serum lipoproteins. However, elevated serum PLTP levels following treatment with topoisomerase I inhibitors in cancer patients may serve as a biomarker for monitoring the development of hypertriglyceridemia and acute pancreatitis.

*Corresponding author at: Department of Medicine, The University of Toledo, College of Medicine, 3000 Arlington Avenue, BHS Room 308, Toledo, OH 43614, United States. Tel.: +1 419 383 3502; fax: +1 419 383 4473 khew-voon.chin@utoledo.edu (K.V. Chin).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Topoisomerase I inhibitor; camptothecin; topotecan; phospholipid transfer protein; high-density lipoprotein; pancreatitis; hyperlipidemia; hypertriglyceridemia

1. Introduction

The emergence of drug resistance in cancer remains a major unresolved problem. Drug resistance may arise intrinsically during tumorigenesis, or it may be acquired through selection following exposure to chemotherapeutic agents. Whether it is intrinsic or acquired resistance, the vastly altered transcriptome of cancer cells during tumor progression or following drug exposure, could result in the expression of multiple genes that contribute to drug resistance [1]. These changes in the cancer transcriptome as well as mutation in drug targets can cause functional changes in some biological pathways including DNA repair, drug transport and metabolism, that result in drug resistance in cancer [2]. Alternatively, exposure to chemotherapy may select for tumor cells, which contained adapted transcriptome that is permissive for growth and survival in the presence of cytotoxic anticancer agents. These global changes in the cancer genome and transcriptome underlie the complexity of the drug resistance phenotype encountered in cancer treatment. Therefore, understanding the dynamic changes in the cancer transcriptome may reveal the complex pathways that contribute to clinical resistance to drug therapy [3].

The discovery of P-glycoprotein and its related proteins, encoded by the superfamily of ATP-binding cassette (ABC) genes, which are transmembrane multidrug transporters that confer resistance to multiple chemotherapeutic agents in cell culture and animal models [4], raised the possibility that targeting either its expression or disrupting its transport activity in cancer, can circumvent the multidrug resistance phenotype and improve chemotherapeutic efficacy and outcome [5]. However, most clinical studies to date showed that the addition of multidrug resistance modulators such as valspodar (PSC 388) to chemotherapeutic regimens did not significantly improve treatment outcome in acute myeloid leukemia [6,7], multiple myeloma [8], advanced ovarian and primary peritoneal cancer [9,10], as well as metastatic breast cancer [11], thus prompting questions about the role of the family of ABC transporters in clinical drug resistance. This leaves open the possibility that during tumorigenesis, the genetic alteration of various genes coupled with the aberrantly perturbed biological pathways may be the underlying factors in chemotherapeutic resistance.

Camptothecin, which was discovered in a National Cancer Institute cytotoxic drug screening program almost 30 years ago, and its derivatives are anticancer agents that inhibit DNA topoisomerase I and exhibit efficacy against a broad spectrum of cancers clinically [12]. Mechanisms of resistance to CPT and its analogues have been reported, which include overexpression of the breast cancer resistance protein, BCRP/MXR/ABCP, loss of DNA mismatch repair, elevation of DNA polymerases and topoisomerase II, as well as topoisomerase I mutations and down-regulation [13], suggesting that the mechanisms of resistance to the CPT family of agents are diverse.

In the course of studying the pharmacological effects of topotecan, a semi-synthetic analogue of CPT, in the human hepatoblastoma HepG2 cell, we found a striking induction of the phospholipid transfer protein (PLTP) gene expression in a dose- and temporal-dependent manner. PLTP is a major serum protein involves in reverse cholesterol transport by shuttling phospholipids and cholesterol from triglyceride-rich lipoproteins to the high-density lipoprotein (HDL) for hepatic uptake by the BI class of scavenger receptor (SR-BI) [14–16]. We showed that CPT is not a substrate for PLTP-mediated shuttling into HDL in mice. We

speculate that the induction of PLTP expression by CPTs may serve as a biomarker for predicting the development of hypertriglyceridemia and acute pancreatitis in cancer patients treated with these agents.

2. Materials and Methods

2.1 Cell Culture and Reagents

HepG2 cells were purchased from the American Type Culture Collection and cultured at 37°C with 10% CO₂ in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 2 mM L-glutamine, 100 µg/ml streptomycin sulfate, and 100 U/ml penicillin. A HepG2 subline harboring a luciferase reporter driven by the promoter of the PLTP gene was generated by transfection of the reporter into HepG2 cells followed by selection in 1.6 mg/ml G418, and a G418 resistant subline stably expressing the reporter was derived and maintained in selection for drug-induced transactivation experiments.

Camptothecin, topotecan, mitoxantrone, cisplatin, cholesterol, taxol, melphalan, Adriamycin, aldosterone, methyl jasmonate, cytarabine (Ara-C), puromycin, rolipram, and staurosporine, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), phorbol 12-myristate 13-acetate 4-O-methyl ether, and 4α-TPA were purchased from Sigma-Aldrich (St. Louis, MO). 9- and 12-amino-20 (S)-CPT, 9-amino-10,11-methylenedioxy-20(R,S)-CPT, and coralyne were gifts of Dr. Leroy Liu (Robert Wood Johnson Medical School, UMDNJ, Piscataway, NJ).

2.2 Gene Expression Profiling of Topotecan in HepG2 cells

HepG2 cells were treated with topotecan and RNAs were isolated using the TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. cDNA targets were synthesized from the isolated total RNA with ³³P-dCTP by oligo-dT-primed polymerization using Superscript II reverse transcriptase and the labeled targets were hybridized to nylon membrane arrays, containing approximately 2,500 cDNAs corresponding to known genes in the GenBank database, washed and exposed on phosphorimage screen for approximately 15 hrs, and then scanned on a Molecular Dynamics Typhoon Phosphorimager. Scanned images of microarrays were analyzed using Imagen (Biodiscovery) and the output intensity data were subjected to cluster analysis using the Cluster and TreeView software suite [17].

2.3 Viral Infection and PLTP Promoter

Adenovirus harboring either the wild-type or the dominant negative mutant of PKCα, βII, and δ has been previously described [18,19]. In brief, adenovirus harboring the various PKCs was obtained from culture supernatant of HEK293a cells previously infected with the corresponding viruses following characterization of virus titers. HepG2 cells were subsequently infected with the PKC adenovirus, and 24 hrs following infection, cells were treated with 500 nM topotecan for an additional 15 hrs, and then harvested for luciferase reporter assay. Transactivation was compared to control cells infected with adenovirus harboring the green fluorescence protein (GFP).

PLTP gene promoter was isolated as previously described [20,21] and amplified by polymerase chain reaction from the human PAC clone RP3-337018, and subcloned into the pGL3-Basic luciferase reporter construct (Promega) that was modified to contain the geneticin (G418)-resistant marker and sequence verified. HepG2 cells were then transfected with the PLTP promoter reporter and selected for G418 resistant clones at 1.6 mg/ml G418, to generate a subline that stably expressed the promoter reporter.

2.4 Northern and Western Blot Analysis

Time-course and dose-response experiments were conducted with either the HepG2 cells or the luciferase reporter subline by exposure to either 500 nM topotecan for various times (1–24 hrs), or with various doses of topotecan (1–1000 nM) for 24 hrs. For Northern blot analysis, total RNA prepared from these cells was subsequently fractionated on 1% formaldehyde denaturing agarose gel and then transferred to nylon membrane for hybridization with radiolabelled cDNA probe of PLTP.

C57BL/6 mice were given, by intraperitoneal injection, various doses of topotecan (2, 5, and 10 mg/kg) and serum was collected from the mice 24 hrs following treatment and PLTP levels were assessed by fractionating 5 µl of serum on 12% SDS-PAGE and then transferred to a 0.45 micron pure nitrocellulose membrane (Bio-Rad). Blots were probed with anti-PLTP antibodies (BioVision, #3595-100) in phosphate-buffered saline containing 5% nonfat dry milk powder and incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Amersham Biosciences, #NA934). Protein bands were resolved using HyGLO HRP detection kit (Denville, #34080 or 34094).

2.5 PLTP Activity Assay

PLTP activity was measured using a fluorescence-based assay kit (Cardiovascular Targets Inc., New York, NY) that contained a donor molecule comprised of a fluorescent self-quenched phospholipid that is transferred to an acceptor molecule in the presence of PLTP, resulting in an increase in fluorescence. Briefly, either 3 µl of mouse serum or 50 µg of protein concentrated from HepG2 culture conditioned media was incubated with donor and acceptor molecules and changes in fluorescence intensity were measured on a BMG Labtech POLARstar fluorescence microplate reader (Ex. = 465 nm; Em. = 535 nm).

2.6 Fractionation of Plasma Lipoproteins by Density Gradient Ultracentrifugation

Male C57BL/6 mice weighing 18–20 g were given either 50 µCi [1,2-³H(N)]-cholesterol or [14-³H(N)]-camptothecin ([³H]-CPT) (Moravsek Biochemicals, Brea, CA) intraperitoneally in 0.2 ml of saline buffer. Blood samples were collected from the animals by cardiac puncture at 0.5, 2, 6, 12, 24, and 36 hours, and plasma was separated by centrifugation at 3,000 rpm for 10 minutes at 4°C. Lipoproteins isolation was performed as described previously [22]. In brief, plasma sample was adjusted by refractometry to a density of 1.24 g/ml with KBr, and the solution was overlaid sequentially on a stepwise NaCl-KBr-gradient (density 1.12–1.06 g/ml), followed by ultracentrifugation at 36,000 × g in a swing-out SW-40 rotor for 9 hr. The resolved very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) were collected by bottom puncture in twenty-four 0.5 ml each fractions. Distribution of [1,2-³H(N)]-cholesterol and [14-³H(N)]-camptothecin in the lipoproteins was determined by liquid scintillation counting of each fraction. Fractions 8, 18, and 24 correspond to peak HDL, LDL and VLDL distribution respectively.

3. Results

To understand the pharmacological response to CPT and its derivatives, and the development of resistance to these agents, we examined by gene expression profiling the transcriptional changes in HepG2 cells following exposure to topotecan. Time-course and dose-response analyses showed modest changes in the expression of a handful of genes, except for the profound induction of the PLTP gene expression by topotecan in a dose- and temporal-dependent manner (Fig. 1). We observed a 20-fold induction of the PLTP gene by topotecan (0.5 µM) (Fig. 1A) that peaked at approximately 24 hrs (Fig. 1B), suggesting that PLTP expression is temporally regulated as a late response gene following drug treatment. The induction of PLTP gene expression by topotecan was confirmed by Northern blot analysis in

a dose-response study (Fig. 1C). We further assessed the induction of PLTP expression by topotecan in various cell types and found its expression activated by topotecan in HepG2 cells only (Fig. 1D).

We next evaluated the induction of PLTP expression by other topoisomerase I inhibitors. Northern blot analysis showed that in addition to topotecan, PLTP expression was also induced by CPT, 9-amino-20(S)-CPT (9-NH₂-CPT(S)), 9-amino-10,11-methylenedioxy-20(S)-CPT (9-NH₂-MD-CPT(S)), and the proto-berberine coralyne, which belongs to a new class of organic cations that are dual poisons of topoisomerase I and II (Fig. 2A) [23,24]. The 9-NH₂-10,11-MD-CPT(R) enantiomer and the prodrug, irinotecan (CPT-11), that are inactive against topoisomerase I, did not induced PLTP expression. The cytotoxic anti-microtubule, vinblastine, as well as cholesterol, a substrate of PLTP, also failed to induce PLTP expression (Fig. 2A).

To facilitate the characterization of the transcriptional activation of PLTP gene expression, a HepG2 subline stably expressing the PLTP promoter reporter was generated that exhibited response to topotecan induction in a time- and dose-dependent manner (Fig. 2B and C). Topoisomerase I inhibitors that induce PLTP expression (Fig. 2A) predictably transactivated the PLTP gene promoter reporter, while the inactive 9-NH₂-MD-CPT(R) enantiomer, and mitoxantrone (topoisomerase II inhibitor) did not (Fig. 2D). Transactivation from PLTP promoter seemed to be specific to the topoisomerase I inhibitors, as other anticancer agents including taxol, melphalan, and adriamycin, the mineralocorticoid aldosterone, the plant hormone methyl jasmonate, and the phosphodiesterase inhibitor rolipram, had no significant effects on the promoter activity (Fig. 2E). Modest transactivation of the promoter was observed with cytarabine (Ara-C) and puromycin. Interestingly, the phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), strongly transactivated the PLTP promoter activity (Fig. 2E).

Since TPA is a potent activator of protein kinase C (PKC) [25,26], we further examined the effects of other phorbol esters including 4 α -TPA and phorbol 12-myristate 13-acetate 4-O-methyl ether (mPMA), which are incapable of activating PKC, and showed that these compounds had no effect on PLTP promoter activity compared to TPA (Fig. 3A). Staurosporine, a potent protein kinase inhibitor including PKC [27], inhibited topotecan- and TPA-mediated transactivations of the PLTP promoter (Fig. 3A), thus suggesting that topotecan- and TPA-induced PLTP gene expression may be regulated via the PKC signaling pathway.

There are at least 10 PKC isotypes in the mammalian genome that can be classified into subtypes due to their distinct structural as well as biochemical properties [28]. To further determine whether specific PKC isozymes contribute to the regulation of PLTP gene expression by topotecan, we examined the effects of some dominant negative mutant of PKCs [18,19] on the transactivation of PLTP promoter activity. Overexpression of either PKC α or PKC β II dominant negative mutant that inactivates their corresponding enzymatic activities did not affect topotecan-mediated transactivation of the PLTP promoter (Fig. 3B). Inactivation of PKC δ , in contrast, attenuated the transactivation of the PLTP promoter by topotecan, suggesting the potential requirement for specific PKC isozyme in the regulation of PLTP gene expression.

Promoter deletion analysis showed that abolition of two putative sterol-response elements (SREs) as well as an Sp1 site in the promoter between nucleotides -888 and -639 markedly attenuated topotecan-induced transactivation by approximately 50% (Fig. 4), suggesting that the sterol response element binding protein (SREBP) might mediate the transactivation of PLTP by topotecan and other topoisomerase I inhibitors.

To determine the induction of PLTP by topotecan *in vivo*, mice were given increasing doses of topotecan and serum was collected for assessing PLTP levels by Western blot analysis. We found significant increase in serum PLTP levels 24 hrs following a single dose of 10 mg/kg of topotecan that was accompanied by an increase in PLTP enzymatic activity (Fig. 5A and B). Since transgenic mice that overexpressed PLTP exhibit marked changes in serum HDL-cholesterol levels [29, 30], we examined the serum lipid profile of topotecan treated mice and observed an increase in total serum cholesterol and triglyceride levels at 10 mg/kg of topotecan. Unexpectedly, HDL-cholesterol level was almost abolished in mice treated with 10 mg/kg of topotecan (Fig. 5C). In addition, HepG2 cells treated with 500 nM of topotecan also exhibited increase in PLTP activity in the conditioned media collected 24 hrs following drug treatment (data not shown).

Since cholesterol and phospholipids are substrates of PLTP, we asked whether topoisomerase I inhibitors might also be substrate for PLTP-mediated transfer into HDL for transport to the liver and subjected to hepatic metabolism. To test this hypothesis, mice were given a dose of [³H]-CPT and serum was collected from treated animals at various time points to determine the distribution of the radiolabelled drug in lipoproteins following isopycnic centrifugation. Our results showed that CPT was not transferred into lipoproteins by PLTP due to the absence of [³H]-CPT in the VLDL, LDL and HDL fractions in the serum of treated animals, but was distributed mainly in the albumin fraction, which was found in the bottom fractions, two hours following drug treatment (Fig. 6). In contrast, [³H]-cholesterol was incorporated and distributed in a time-dependent manner, first in the chylomicron/VLDL fraction, and then transitioning into the LDL and HDL fractions as time progressed, with a majority of the cholesterol transported by LDL (Fig. 6). These results suggested that topoisomerase I inhibitors are not substrate for PLTP shuttling into HDL for reverse cholesterol transport to the liver.

4. Discussion

Drug resistance in cancer is a complex process associated with the alterations of multiple genetic factors and the transcriptome of the cancer cells. These aberrant changes during tumorigenesis result in the perturbation of biological pathways that may contribute to the drug resistant phenotype. Therefore, understanding how drug resistance emerges in cancer is of paramount importance in improving cancer treatment and outcome. In this report, we identified the transcriptional induction of PLTP gene expression by CPT and its derivatives that are active inhibitor of the topoisomerase I enzyme (Figs. 1 and 2). Induction of PLTP expression was specific to CPT and its family of topoisomerase I poisons, and also restricted to the human liver cancer HepG2 cells. We showed further that topotecan induced PLTP expression is mediated through the PKC signaling pathway and requires specific PKC isozyme for its transcriptional regulation (Fig. 3). PLTP expression is also induced *in vivo* in mice following treatment with topotecan that is accompanied by a rise in serum triglyceride and cholesterol, and a marked loss of HDL (Fig. 5). In addition, CPT induced increase in PLTP level did not result in the transfer of CPT to HDL.

The profound induction of PLTP expression by CPTs is intriguing, which led us to initially hypothesize that topoisomerase I inhibitors induced their own metabolism via the reverse cholesterol transport pathway. Moreover, it has been shown that cholesterol is a substrate for PLTP [31], and high cholesterol diet increases PLTP activity and PLTP mRNA in mice [32, 33]. In addition, crystal structure data of the bacterial permeability increasing (BPI) protein [34,35] and the cholesteryl ester transfer protein (CETP) [36] showing that proteins in this family, including PLTP, contained intrinsic lipid binding sites that appear to act as carrier proteins or channels that shuttle and redistribute lipids between lipoproteins. These observations raised the possibility that CPTs might be substrates for PLTP-mediated transfer into HDL and subsequently transported to the liver for metabolism via the reverse cholesterol

transport pathway. However, our results showed that, unlike cholesterol, CPT was not found in HDL or other lipoproteins, suggesting that CPTs are not substrates for PLTP and thus ruling out the possibility of PLTP-mediated transfer of CPT into HDL for liver metabolism. These observations pose the possibility that the induction of PLTP gene expression by CPTs is merely the result of bystander effect following drug exposure, which inadvertently activates the expression of many genes, and some of which including PLTP may have no physiological consequences or whose functional impacts are unknown.

Besides topotecan, it has previously been reported that PLTP expression is induced by hypoxia [37], fenofibrate [38], and the liver X receptor (LXR) agonist, T0901317 [39]. These results suggest that PLTP expression is responsive to stimulation by small pharmacological molecules. While PLTP mRNA is found abundantly in a variety of tissues [40], however, the induction by topotecan is cell-type specific. The underlying reason for this conditional expression pattern is unclear, and we speculate that it may be dependent on the small pharmacological molecules as well as the presence of specific transcriptional regulators in the respective tissues or cell-types.

Another curious observation in our study is the unexpected rise in serum cholesterol and triglyceride levels, and a severe depletion of serum HDL in mice treated with a high dose of topotecan. The abrupt rise in serum triglyceride is known to be associated with the onset of acute pancreatitis [41]. Though under-reported and under-appreciated, drug-induced acute pancreatitis are commonly encountered in drug therapy [42]. The etiologic cause of most drug-induced acute pancreatitis and atherosclerosis may be associated with hyperlipidemia, resulting from increased total serum triglyceride and cholesterol levels [43]. The mechanisms of drug-induced hyperlipidemia are unknown. Increase in PLTP activity has been linked to hypertriglyceridemia [44,45], which may trigger the onset of acute pancreatitis [43,46]. It is noteworthy that acute pancreatitis has been reported in cancer patients treated with topoisomerase I inhibitors such as irinotecan [47] and exatecan [48], as well as other chemotherapeutic agents including L-asparaginase [49,50], tamoxifen [51], interferon α [52], and capecitabine [53]. These observations, together with our results, suggest that hypertriglyceridemia induced acute pancreatitis may be correlated with the increase in PLTP, thus suggesting that PLTP may serve as a biomarker for CPTs and other drug-induced hypertriglyceridemia and acute pancreatitis.

In summary, our results showed that CPTs induced PLTP expression may have no functional consequence on drug resistance in cancer, but instead may be associated with drug-induced hyperlipidemia that triggers the onset of acute pancreatitis. Therefore, monitoring the changes in serum PLTP levels or activity may serve as an important biomarker for drug-induced hyperlipidemia and the development of acute pancreatitis. How an increase in PLTP expression causes hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) and lowers HDL levels needs to be further investigated.

Acknowledgments

This research was supported in part by National Institutes of Health grant R01 CA102204.

References

1. Chin KV, Alabanza L, Fujii K, Kudoh K, Kita T, Kikuchi Y, et al. Application of expression genomics for predicting treatment response in cancer. *Ann N Y Acad Sci* 2005;1058:186–95. [PubMed: 16394136]
2. Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. *Br J Cancer* 2008;99:387–91. [PubMed: 18665178]

3. Alaoui-Jamali MA, Dupre I, Qiang H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. *Drug Resist Updat* 2004;7:245–55. [PubMed: 15533762]
4. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. *FEBS Lett* 2006;580:998–1009. [PubMed: 16405967]
5. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov* 2006;5:219–34. [PubMed: 16518375]
6. Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. *Br J Haematol* 2009;145:318–32. [PubMed: 19291085]
7. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. *Blood* 2002;100:1224–32. [PubMed: 12149202]
8. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, et al. Phase III study of PSC-833 (valsopodar) in combination with vincristine, doxorubicin, and dexamethasone (valsopodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. *Cancer* 2006;106:830–8. [PubMed: 16419071]
9. Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, et al. Phase III study of valsopodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. *J Clin Oncol* 2008;26:2674–82. [PubMed: 18509179]
10. Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, et al. Phase II study of paclitaxel and valsopodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. *J Clin Oncol* 2001;19:2975–82. [PubMed: 11408492]
11. Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, et al. A pilot phase II trial of valsopodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. *Cancer Invest* 2006;24:677–81. [PubMed: 17118777]
12. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer* 2006;6:789–802. [PubMed: 16990856]
13. Beretta GL, Perego P, Zunino F. Mechanisms of cellular resistance to camptothecins. *Curr Med Chem* 2006;13:3291–305. [PubMed: 17168852]
14. Groen AK, Oude Elferink RP, Verkade HJ, Kuipers F. The ins and outs of reverse cholesterol transport. *Ann Med* 2004;36:135–45. [PubMed: 15119833]
15. Albers JJ, Cheung MC. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. *Curr Opin Lipidol* 2004;15:255–60. [PubMed: 15166780]
16. Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. *Obes Rev* 2009;10:403–11. [PubMed: 19413703]
17. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 1998;95:14863–8. [PubMed: 9843981]
18. Oka M, Hitomi T, Okada T, Nakamura Si S, Nagai H, Ohba M, et al. Dual regulation of phospholipase D1 by protein kinase C alpha in vivo. *Biochem Biophys Res Commun* 2002;294:1109–13. [PubMed: 12074591]
19. Oka M, Okada T, Nakamura S, Ohba M, Kuroki T, Kikkawa U, et al. PKCdelta inhibits PKCalpha-mediated activation of phospholipase D1 in a manner independent of its protein kinase activity. *FEBS Lett* 2003;554:179–83. [PubMed: 14596936]
20. Tu AY, Wolfbauer G, Albers JJ. Functional characterization of the promoter region of the human phospholipid transfer protein gene. *Biochem Biophys Res Commun* 1995;217:705–11. [PubMed: 8554588]
21. Tu AY, Wolfbauer G, Chen H, Albers JJ. DNA sequences essential for transcription of human phospholipid transfer protein gene in HepG2 cells. *Biochem Biophys Res Commun* 1997;232:574–7. [PubMed: 9125225]

22. Kleinvelde HA, Duif PF, Pekelharing HL, van Rijn HJ. Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions. *Biochim Biophys Acta* 1996;1303:15–21. [PubMed: 8816848]
23. Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, et al. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. *Cancer Res* 1996;56:2795–800. [PubMed: 8665516]
24. Makhey D, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. *Bioorg Med Chem* 1996;4:781–91. [PubMed: 8818227]
25. Nishizuka Y, Kikkawa U. Early studies of protein kinase C: a historical perspective. *Methods Mol Biol* 2003;233:9–18. [PubMed: 12840494]
26. Parker PJ, Murray-Rust J. PKC at a glance. *J Cell Sci* 2004;117:131–2. [PubMed: 14676268]
27. Swannie HC, Kaye SB. Protein kinase C inhibitors. *Curr Oncol Rep* 2002;4:37–46. [PubMed: 11734112]
28. Ohno S, Nishizuka Y. Protein kinase C isotypes and their specific functions: prologue. *J Biochem (Tokyo)* 2002;132:509–11. [PubMed: 12359062]
29. Albers JJ, Tu AY, Paigen B, Chen H, Cheung MC, Marcovina SM. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. *Int J Clin Lab Res* 1996;26:262–7. [PubMed: 9007618]
30. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. *J Clin Invest* 1996;98:2373–80. [PubMed: 8941656]
31. Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. *J Biol Chem* 1993;268:23098–105. [PubMed: 8226827]
32. Jiang XC, Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. *J Biol Chem* 1995;270:17133–8. [PubMed: 7615508]
33. Tu AY, Paigen B, Wolfbauer G, Cheung MC, Kennedy H, Chen H, et al. Introduction of the human PLTP transgene suppresses the atherogenic diet-induced increase in plasma phospholipid transfer activity in C57BL/6 mice. *Int J Clin Lab Res* 1999;29:14–21. [PubMed: 10356658]
34. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. *Science* 1997;276:1861–4. [PubMed: 9188532]
35. Huuskonen J, Wohlfahrt G, Jauhiainen M, Ehnholm C, Teleman O, Olkkonen VM. Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis. *J Lipid Res* 1999;40:1123–30. [PubMed: 10357844]
36. Qiu X, Mistry A, Ammirati MJ, Chrnyk BA, Clark RW, Cong Y, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. *Nat Struct Mol Biol* 2007;14:106–13. [PubMed: 17237796]
37. Jiang XC, D'Armiento J, Mallampalli RK, Mar J, Yan SF, Lin M. Expression of plasma phospholipid transfer protein mRNA in normal and emphysematous lungs and regulation by hypoxia. *J Biol Chem* 1998;273:15714–8. [PubMed: 9624168]
38. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, et al. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. *J Biol Chem* 2001;276:25841–7. [PubMed: 11342537]
39. Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. *J Biol Chem* 2002;277:39561–5. [PubMed: 12177004]
40. Albers JJ, Wolfbauer G, Cheung MC, Day JR, Ching AF, Lok S, et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. *Biochim Biophys Acta* 1995;1258:27–34. [PubMed: 7654777]
41. Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. *Med Clin North Am* 2008;92:889–923. ix–x. [PubMed: 18570947]

42. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. *Am J Gastroenterol* 1999;94:2417–22. [PubMed: 10484002]
43. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. *J Clin Gastroenterol* 2003;36:54–62. [PubMed: 12488710]
44. Jonkers IJ, Smelt AH, Hattori H, Scheek LM, van Gent T, de Man FH, et al. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. *J Lipid Res* 2003;44:1462–9. [PubMed: 12754275]
45. Kaser S, Laimer M, Sandhofer A, Salzmann K, Ebenbichler CF, Patsch JR. Effects of weight loss on PLTP activity and HDL particle size. *Int J Obes Relat Metab Disord* 2004;28:1280–2. [PubMed: 15365582]
46. Miller JP. Serum triglycerides, the liver and the pancreas. *Curr Opin Lipidol* 2000;11:377–82. [PubMed: 10945719]
47. Govindan R, Read W, Faust J, McLeod H. Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer. *Oncology (Huntingt)* 2003;17:27–9.
48. De Jager R, Cheverton P, Tamanoi K, Coyle J, Ducharme M, Sakamoto N, et al. DX-8951f: summary of phase I clinical trials. *Ann N Y Acad Sci* 2000;922:260–73. [PubMed: 11193901]
49. Jain S, Naithani R, Kapoor G, Nath T. L-asparaginase induced severe hypertriglyceridemia in acute lymphoblastic leukemia with 11q23 abnormality. *Leuk Res* 2009;33:e194. [PubMed: 19487026]
50. Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. *Blood* 1997;89:1886–95. [PubMed: 9058708]
51. Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. *Clin Drug Investig* 2006;26:297–302.
52. Wong SF, Jakowatz JG, Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. *Ann Pharmacother* 2004;38:1655–9. [PubMed: 15304625]
53. Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP. Capecitabine-induced hypertriglyceridemia: a report of two cases. *Anticancer Res* 2006;26:2249–51. [PubMed: 16821596]

Figure 1.

Induction of PLTP gene expression by topotecan. RNA was isolated from HepG2 cells for gene expression profiling analysis following treatment with topotecan either in a time course study (500 nM topotecan) at the various times indicated (**A**), or dose-response analysis (0, 1, 100, 500, and 1,000 nM) for 24 hrs (**B**). The dendrograms showed the induction of PLTP expression normalized to untreated control. **C**, validation of topotecan induced PLTP expression in a dose response study by Northern blot analysis. **D**, cell-type specific induction of PLTP expression by topotecan (+) compared to untreated control (-) in various cancer cells; 1, 2008 (ovarian carcinoma); 2, A2780 (ovarian carcinoma); 3, A549 (lung adenocarcinoma); 4 and 10, HepG2 (hepatoma); 5, KB-3-1 (oral cancer); 6, KB-V-1 (multidrug-resistant cells derived KB-3-1); 7, MCF-7 (mammary carcinoma); 8, U937 (myeloid leukemia); and 9, PC3M (metastatic prostate carcinoma).

Figure 2.

Induction of PLTP gene expression by anticancer drugs. **A**, Northern blot analysis of CPT and its analogues on PLTP gene expression. Except for CPT (10 nM), HepG2 cells were exposed to all other drugs at 1 μ M for 24 hrs prior to RNA isolation for Northern analysis. **B** and **C**, transactivation of the PLTP gene promoter activity in a HepG2 subline harboring the luciferase reporter driven by the PLTP gene promoter in a time- and dose-dependent induction by topotecan. In the time-course analysis, cells were treated with 1 μ M topotecan at the indicated times, in the dose-response study, cells were treated with topotecan at the indicated doses for 24 hrs. **D** and **E**, transactivation of the PLTP gene promoter activity was recapitulated with CPT and its analogues (**D**) as in Figure 2A, and by various other drugs (**E**). Cells were exposed

to 1 μ M of drug, except for CPT (10 nM) and TPA (30 ng/ml) for 24 hrs. All reporter assays were performed in triplicate and results are means $\pm$ s.e.m.

Figure 3.

Characterizing the transcriptional regulation of PLTP gene expression by topotecan and PKC. **A**, transactivation of PLTP gene promoter activity by topotecan (0.5 μ M) and TPA (30 ng/ml) is inhibited by staurosporine (300 nM). Non-PKC activators, 4 α -TPA and mPMA (30 ng/ml each), failed to transactivate PLTP promoter activity. **B**, transactivation of PLTP promoter reporter by topotecan (0.5 μ M) is partially inhibited by a dominant negative mutant of PKC δ , but not PKC α or β II, compared to HepG2 cells transduced with adenovirus expressing GFP that were either untreated (-) or treated (+) with topotecan. In **A** and **B**, cells were exposed to drugs for 24 hrs before harvesting for the reporter assay. Results are in triplicate and error bars indicate means $\pm$ s.e.m.

Figure 4. PLTP promoter deletion analysis. Progressive deletion of a 1.5 kb proximal promoter of the PLTP gene was made as indicated, which showed that deleting the upstream SRE binding sites reduced topotecan (0.5 μ M) transactivation by approximately 50%. All experiments were performed in triplicate and treated with topotecan for 24 hrs. Error bars indicate s.e.m.

Figure 5. Effects of topotecan on serum PLTP and lipid profile in mice. **A**, Western blot analysis of serum PLTP levels in mice following topotecan treatment (0, 2, 5, and 10 mg/kg). Coomassie stained of a portion of the gel is shown in the lower panel. **B** and **C**, serum PLTP activity (**B**) and lipid profile (**C**) of mice treated with topotecan as in **A**. HDL-C, serum HDL cholesterol; TC, total cholesterol; and TG, triglyceride. Where appropriate, experiments were performed in triplicate and results are mean $\pm$ s.e.m.

Figure 6.

Distribution of $[^3\text{H}]$ -CPT and $[^3\text{H}]$ -cholesterol in lipoproteins. Mice were given 50 μCi of either $[^3\text{H}]$ -CPT or $[^3\text{H}]$ -cholesterol and serum was collected at the time points indicated and subjected to isopycnic ultracentrifugation to determine the distribution of $[^3\text{H}]$ -CPT or $[^3\text{H}]$ -cholesterol in serum lipoproteins as described in **Materials and Methods**. The arrows indicate the peak fractions corresponding to VLDL, LDL, and HDL.